{"id":571091,"date":"2025-12-08T00:00:00","date_gmt":"2025-12-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0070-2025-biopharma-opioid-induced-constipation-current-treatment-treatment-algorithms-claims-data-analysis\/"},"modified":"2026-03-31T10:24:05","modified_gmt":"2026-03-31T10:24:05","slug":"algoim0070-2025-biopharma-opioid-induced-constipation-current-treatment-treatment-algorithms-claims-data-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0070-2025-biopharma-opioid-induced-constipation-current-treatment-treatment-algorithms-claims-data-analysis\/","title":{"rendered":"Opioid-Induced Constipation &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Opioid-Induced Constipation (US)"},"content":{"rendered":"<p>Opioid-induced constipation (<abbr title=\"opioid-induced constipation\">OIC<\/abbr>) is a condition in which bowel movements are infrequent or incomplete as a result of opioid medications. The treatment of <abbr title=\"opioid-induced constipation\">OIC<\/abbr> relies on various prescription medications, including several agents approved for irritable bowel syndrome with constipation (<abbr title=\"constipation-predominant irritable bowel syndrome\">IBS-C<\/abbr>) or chronic idiopathic constipation (<abbr title=\"chronic idiopathic constipation\">CIC<\/abbr>) and used off-label. Established treatments for <abbr title=\"opioid-induced constipation\">OIC<\/abbr> such as Linzess (used off-label) and Movantik have a relatively constant patient share, but drug-treatment rates are low because many patients opt for over-the-counter (<abbr title=\"over-the-counter\">OTC<\/abbr>) therapies. As a result, drugs such as Symproic, which is <abbr title=\"Food and Drug Administration\">FDA<\/abbr>-approved to treat <abbr title=\"opioid-induced constipation\">OIC<\/abbr>, struggle to gain market share. This therapy market is also characterized by low persistency and compliance rates. In this report, we offer insight into current prescribing trends for <abbr title=\"opioid-induced constipation\">OIC<\/abbr> in the United States based on real-world claims data.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"opioid-induced constipation\">OIC<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"opioid-induced constipation\">OIC<\/abbr> patients?<\/li>\n<li>How have Symproic and Motegrity been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr title=\"opioid-induced constipation\">OIC<\/abbr> patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"opioid-induced constipation\">OIC<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies:<\/strong> Allergan, Ironwood, Synergy Pharma, Takeda, Mallinckrodt, Alfasigma, AstraZeneca, Daiichi Sankyo, Salix Pharmaceuticals, Endo Pharma<\/p>\n<p><strong>Key drugs: <\/strong>Motegrity, Linzess, Ibsrela, Relistor, Symproic, Movantik, Amitiza, Trulance, Naloxone, osmotic laxatives<\/p>\n<p><b>Key feature: <\/b>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-571091","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastrointestinal","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571091\/revisions"}],"predecessor-version":[{"id":571252,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571091\/revisions\/571252"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=571091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}